Assignee
MELIOR PHARMACEUTICALS I INC
US·12 granted patents·7 pending applications·82 citations·filing 2006–2024
Top patents by PatentIndex Score
19 records- 0194US8343985B2Methods for modulating Lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2010·Granted Jan 1, 2013·17 cites·13 claims
- 0294US7776870B2Methods for modulating Lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2006·Granted Aug 17, 2010·22 cites·18 claims
- 0393US11534442B2Treatment of adipocytesMELIOR PHARMACEUTICALS I INC·Filed 2020·Granted Dec 27, 2022·6 cites·5 claims
- 0492US8835448B2Methods and formulations for modulating lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2012·Granted Sep 16, 2014·11 cites·20 claims
- 0591US9216959B2Methods and formulations for treating cardiovascular diseaseMELIOR PHARMACEUTICALS I INC·Filed 2014·Granted Dec 22, 2015·10 cites·21 claims
- 0690US10251883B2Methods and formulations for modulating Lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2017·Granted Apr 9, 2019·5 cites·18 claims
- 0789US11033548B2Methods and formulations for modulating Lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2019·Granted Jun 15, 2021·4 cites·7 claims
- 0886US10786503B2Treatment of adipocytesMELIOR PHARMACEUTICALS I INC·Filed 2018·Granted Sep 29, 2020·6 cites·5 claims
- 0978US12070461B2Methods and formulations for modulating Lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2021·Granted Aug 27, 2024·0 cites·16 claims
- 1077US12064432B2Treatment of adipocytesMELIOR PHARMACEUTICALS I INC·Filed 2022·Granted Aug 20, 2024·0 cites·4 claims
- 1173US12011445B2Prevention of pancreatic cell degenerationMELIOR PHARMACEUTICALS I INC·Filed 2019·Granted Jun 18, 2024·1 cites·13 claims
- 1273US2024316048A1Prevention of Pancreatic Cell DegenerationMELIOR PHARMACEUTICALS I INC·Filed 2024·Application pending·0 cites
- 1362US9763945B2Methods and formulations for modulating Lyn kinase activity and treating related disordersMELIOR PHARMACEUTICALS I INC·Filed 2015·Granted Sep 19, 2017·0 cites·8 claims
- 1454US2020215068A1Treatment of type i and type ii diabetesMELIOR PHARMACEUTICALS I INC·Filed 2020·Application pending·0 cites
- 1551US2021106581A1Treatment Of Liver DiseasesMELIOR PHARMACEUTICALS I INC·Filed 2019·Application pending·0 cites
- 1649US2022031700A1Treatment of Acute Respiratory Distress Syndrome (ARDS)MELIOR PHARMACEUTICALS I INC·Filed 2021·Application pending·0 cites
- 1748US2010152215A1Methods of identifying activators of lyn kinaseMELIOR PHARMACEUTICALS I INC·Filed 2008·Application pending·0 cites
- 1845US2010197710A1Methods Of Activating IRS-1 And AKTMELIOR PHARMACEUTICALS I INC·Filed 2008·Application pending·0 cites
- 1945US2015190396A1Treatment of type i and type ii diabetesMELIOR PHARMACEUTICALS I INC·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when MELIOR PHARMACEUTICALS I INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →